Screening and Surgical Outcomes of Familial Pancreatic Cancer

Surgical Clinics of North America

Volumn 93, Issue 3, 2013, Pages 629-645

  Templeton, Adam W ^a   Brentnall, Teresa A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Familial pancreatic cancer; Intraductal papillary mucinous neoplasm; Mucinous cystic neoplasm; Pancreatic intraepithelial neoplasia; Peutz Jeghers syndrome

Indexed keywords

ADENOMATOUS POLYP; BILE DUCT CANCER; BREAST CANCER; CANCER SCREENING; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; ENDOSCOPIC ECHOGRAPHY; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA SYNDROME; FAMILIAL PANCREATIC CANCER; FEASIBILITY STUDY; FIRST DEGREE RELATIVE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GLUCOSE INTOLERANCE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS ADENOMA; PANCREAS CANCER; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROLOGY; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; CARCINOMA; EARLY DETECTION OF CANCER; GENETIC MARKERS; HUMANS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PRECANCEROUS CONDITIONS; TREATMENT OUTCOME;

EID: 84877001801     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2013.02.002     Document Type: Review

References (72)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29. 10.3322/caac.20138.
2. Shimizu Y., Yasui K., Matsueda K., et al. Small carcinoma of the pancreas is curable: new computed tomography finding, pathological study and postoperative results from a single institute. J Gastroenterol Hepatol 2005, 20(10):1591-1594. 10.1111/j.1440-1746.2005.03895.x.
3. Yeo C.J., Cameron J.L. Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Surg 1998, 383(2):129-133.
4. Rulyak S.J., Kimmey M.B., Veenstra D.L., et al. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 2003, 57(1):23-29. 10.1067/mge.2003.28.
5. Hruban R.H., Canto M.I., Goggins M., et al. Update on familial pancreatic cancer. Adv Surg 2010, 44:293-311.
6. Bartsch D.K., Gress T.M., Langer P. Familial pancreatic cancer-current knowledge. Nat Rev Gastroenterol Hepatol 2012, 9(8):445-453. 10.1038/nrgastro.2012.111.
7. Klein A.P., Brune K.A., Petersen G.M., et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004, 64(7):2634-2638.
8. Schneider R., Slater E.P., Sina M., et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer 2011, 10(2):323-330. 10.1007/s10689-010-9414-x.
9. Tersmette A.C., Petersen G.M., Offerhaus G.J., et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001, 7(3):738-744.
10. Applebaum S.E., Kant J.A., Whitcomb D.C., et al. Genetic testing. Counseling, laboratory, and regulatory issues and the EUROPAC protocol for ethical research in multicenter studies of inherited pancreatic diseases. Med Clin North Am 2000, 84(3):575-588. viii.
11. Audibert A., Rufat P., Maire F., et al. Incidence of pancreatic and extra-pancreatic cancers in the families of patients with pancreatic adenocarcinoma: results of prospective survey. Pancreatology 2002, 2:256.
12. Klein A.P., Beaty T.H., Bailey-Wilson J.E., et al. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 2002, 23(2):133-149. 10.1002/gepi.1102.
13. Petersen G.M., Amundadottir L., Fuchs C.S., et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010, 42(3):224-228. 10.1038/ng.522.
14. Brentnall T.A., Lai L.A., Coleman J., et al. Arousal of cancer-associated stroma: overexpression of palladin activates fibroblasts to promote tumor invasion. PLoS One 2012, 7(1):e30219. 10.1371/journal.pone.0030219.
15. McFaul C.D., Greenhalf W., Earl J., et al. Anticipation in familial pancreatic cancer. Gut 2006, 55(2):252-258. 10.1136/gut.2005.065045.
16. Brune K.A., Lau B., Palmisano E., et al. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst 2010, 102(2):119-126. 10.1093/jnci/djp466.
17. Hemminki K., Li X. Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 2003, 103(4):525-530. 10.1002/ijc.10863.
18. Wang L., Brune K.A., Visvanathan K., et al. Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2009, 18(11):2829-2834. 10.1158/1055-9965.EPI-09-0557.
19. Giardiello F.M., Offerhaus G.J., Lee D.H., et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993, 34(10):1394-1396.
20. Giardiello F.M., Welsh S.B., Hamilton S.R., et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987, 316(24):1511-1514. 10.1056/NEJM198706113162404.
21. Brand R.E., Lerch M.M., Rubinstein W.S., et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007, 56(10):1460-1469. 10.1136/gut.2006.108456.
22. Rulyak S.J., Lowenfels A.B., Maisonneuve P., et al. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 2003, 124(5):1292-1299.
23. Prokopczyk B., Hoffmann D., Bologna M., et al. Identification of tobacco-derived compounds in human pancreatic juice. Chem Res Toxicol 2002, 15(5):677-685.
24. Huxley R., Ansary-Moghaddam A., Berrington de Gonzalez A., et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005, 92(11):2076-2083. 10.1038/sj.bjc.6602619.
25. Lynch S.M., Vrieling A., Lubin J.H., et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 2009, 170(4):403-413. 10.1093/aje/kwp134.
26. Wang W., Chen S., Brune K.A., et al. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007, 25(11):1417-1422. 10.1200/JCO.2006.09.2452.
27. Hruban R.H., Maitra A., Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol 2008, 1(4):306-316.
28. Hruban R.H., Takaori K., Klimstra D.S., et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004, 28(8):977-987.
29. Macgregor-Das A.M., Iacobuzio-Donahue C.A. Molecular pathways in pancreatic carcinogenesis. J Surg Oncol 2012, 10.1002/jso.23213.
30. Baumgart M., Heinmoller E., Horstmann O., et al. The genetic basis of sporadic pancreatic cancer. Cell Oncol 2005, 27(1):3-13.
31. Brune K., Hong S.M., Li A., et al. Genetic and epigenetic alterations of familial pancreatic cancers. Cancer Epidemiol Biomarkers Prev 2008, 17(12):3536-3542. 10.1158/1055-9965.EPI-08-0630.
32. Crnogorac-Jurcevic T., Chelala C., Barry S., et al. Molecular analysis of precursor lesions in familial pancreatic cancer. PLoS One 2013, 8(1):e54830.
33. Andea A., Sarkar F., Adsay V.N. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 2003, 16(10):996-1006. 10.1097/01.MP.0000087422.24733.62.
34. Schwartz A.M., Henson D.E. Familial and sporadic pancreatic carcinoma, epidemiologic concordance. Am J Surg Pathol 2007, 31(4):645-646. 10.1097/PAS.0b013e31802d6d42.
35. Shi C., Klein A.P., Goggins M., et al. Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 2009, 15(24):7737-7743. 10.1158/1078-0432.CCR-09-0004.
36. Brune K., Abe T., Canto M., et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 2006, 30(9):1067-1076.
37. Terhune P.G., Phifer D.M., Tosteson T.D., et al. K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol Biomarkers Prev 1998, 7(6):515-521.
38. Lindgren G., Liljegren A., Jaramillo E., et al. Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer. Gut 2002, 50(2):228-234.
39. Sohn T.A., Yeo C.J., Cameron J.L., et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004, 239(6):788-797. [discussion: 797-9].
40. Abe T., Fukushima N., Brune K., et al. Genome-wide allelotypes of familial pancreatic adenocarcinomas and familial and sporadic intraductal papillary mucinous neoplasms. Clin Cancer Res 2007, 13(20):6019-6025. 10.1158/1078-0432.CCR-07-0471.
41. Luttges J., Zamboni G., Longnecker D., et al. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol 2001, 25(7):942-948.
42. Maguchi H., Tanno S., Mizuno N., et al. Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas: a multicenter study in Japan. Pancreas 2011, 40(3):364-370. 10.1097/MPA.0b013e31820a5975.
43. Rebours V., Couvelard A., Peyroux J.L., et al. Familial intraductal papillary mucinous neoplasms of the pancreas. Dig Liver Dis 2012, 44(5):442-446. 10.1016/j.dld.2011.07.003.
44. Canto M.I., Goggins M., Hruban R.H., et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006, 4(6):766-781. [quiz: 665]. 10.1016/j.cgh.2006.02.005.
45. Nehra D., Oyarvide V.M., Mino-Kenudson M., et al. Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter?. Pancreatology 2012, 12(4):358-363. 10.1016/j.pan.2012.05.011.
46. Lubezky N., Ben-Haim M., Lahat G., et al. Intraductal papillary mucinous neoplasm of the pancreas: associated cancers, family history, genetic predisposition?. Surgery 2012, 151(1):70-75. 10.1016/j.surg.2011.06.036.
47. Cubilla A.L., Fitzgerald P.J. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 1976, 36(7 Pt 2):2690-2698.
48. Pour P.M., Sayed S., Sayed G. Hyperplastic, preneoplastic and neoplastic lesions found in 83 human pancreases. Am J Clin Pathol 1982, 77(2):137-152.
49. Ludwig E., Olson S.H., Bayuga S., et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011, 106(5):946-954. 10.1038/ajg.2011.65.
50. Brentnall T.A., Bronner M.P., Byrd D.R., et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999, 131(4):247-255.
51. Al-Sukhni W., Borgida A., Rothenmund H., et al. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 2012, 16(4):771-783. 10.1007/s11605-011-1781-6.
52. Brat D.J., Lillemoe K.D., Yeo C.J., et al. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998, 22(2):163-169.
53. Harinck F., Nagtegaal T., Kluijt I., et al. Feasibility of a pancreatic cancer surveillance program from a psychological point of view. Genet Med 2011, 13(12):1015-1024. 10.1097/GIM.0b013e31822934f5.
54. Hart S.L., Torbit L.A., Crangle C.J., et al. Moderators of cancer-related distress and worry after a pancreatic cancer genetic counseling and screening intervention. Psychooncology 2011, 10.1002/pon.2026.
55. Maheu C., Vodermaier A., Rothenmund H., et al. Pancreatic cancer risk counselling and screening: impact on perceived risk and psychological functioning. Fam Cancer 2010, 9(4):617-624. 10.1007/s10689-010-9354-5.
56. Kimmey M.B., Bronner M.P., Byrd D.R., et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 2002, 56(Suppl 4):S82-S86.
57. Canto M.I., Goggins M., Yeo C.J., et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004, 2(7):606-621.
58. Vasen H.F., Wasser M., van Mil A., et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-leiden mutation. Gastroenterology 2011, 140(3):850-856. 10.1053/j.gastro.2010.11.048.
59. Canto M.I., Harinck F., Hruban R.H., et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2012, 10.1136/gutjnl-2012-303108.
60. Zubarik R., Gordon S.R., Lidofsky S.D., et al. Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study. Gastrointest Endosc 2011, 74(1):87-95. 10.1016/j.gie.2011.03.1235.
61. Verna E.C., Hwang C., Stevens P.D., et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010, 16(20):5028-5037. 10.1158/1078-0432.CCR-09-3209.
62. Langer P., Kann P.H., Fendrich V., et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009, 58(10):1410-1418. 10.1136/gut.2008.171611.
63. Pannala R., Leibson C.L., Rabe K.G., et al. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 2009, 104(9):2318-2325. 10.1038/ajg.2009.253.
64. Laffan T.A., Horton K.M., Klein A.P., et al. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol 2008, 191(3):802-807. 10.2214/AJR.07.3340.
65. de Jong K., Nio C.Y., Hermans J.J., et al. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroenterol Hepatol 2010, 8(9):806-811. 10.1016/j.cgh.2010.05.017.
66. Canto M.I., Hruban R.H., Fishman E.K., et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012, 142(4):796-804. [quiz: e14-5]. 10.1053/j.gastro.2012.01.005.
67. Poley J.W., Kluijt I., Gouma D.J., et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009, 104(9):2175-2181. 10.1038/ajg.2009.276.
68. Aimoto T., Uchida E., Nakamura Y., et al. Multicentric pancreatic intraepithelial neoplasias (PanINs) presenting with the clinical features of chronic pancreatitis. J Hepatobiliary Pancreat Surg 2008, 15(5):549-553. 10.1007/s00534-007-1269-7.
69. Takaori K., Matsusue S., Fujikawa T., et al. Carcinoma in situ of the pancreas associated with localized fibrosis: a clue to early detection of neoplastic lesions arising from pancreatic ducts. Pancreas 1998, 17(1):102-105.
70. Topazian M., Enders F., Kimmey M., et al. Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. Gastrointest Endosc 2007, 66(1):62-67. 10.1016/j.gie.2006.09.018.
71. Kimmy M.B., Bronner M.P., Byrd D.R., et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 2002, 56(4 Suppl). S82-6.
72. Al-Sukhni W., Borgida A., Rothenmund H., et al. J Gastrointest Surg 2012, 16(4):771-783.